AgeX Therapeutics closes $10 million capital raise
AgeX Therapeutics, a BioTime subsidiary, Inc. announced it has closed its round of equity financing, raising net proceeds of $10 million, valuing AgeX at approximately $68 million post-money. Post-closing, BioTime owns approximately 85% of the outstanding shares of AgeX. August 17, 2017